和记娱乐

VOLUNTARY ANNOUNCEMENT - FIRST DOSE OF THE FIRST BATCH OF SUBJECTS IN PHASE I CLINICAL TRIAL OF TQA3038 "siRNA" COMPLETED

VOLUNTARY ANNUONCEMENT - SINO BIOPHARMACEUTICAL AWARDED "2023 FORBES CHINA ESG INNOVATIVE ENTERPRISE"

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2023

VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIAL FOR TQB3015 "ATR KINASE INHIBITOR" TABLET

VOLUNTARY ANNOUNCEMENT - DISPOSAL OF EQUITY INTERESTS IN THREE SUBSIDIARIES

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2023

VOLUNTARY ANNOUNCEMENT - SINO BIOPHARMACEUTICAL MSCI ESG RATING UPGRADED TO "A"

VOLUNTARY ANNOUNCEMENT - TQG3902 "ANGIOTENSIN II" INJECTION APPROVED FOR CLINICAL TRIAL